First nod in pocket, Camzyos is on its way with supplemental filing

24 October 2022

New Jersey, USA-based cancer giant Bristol Myers Squibb (NYSE: BMY) has had its bid to broaden the label for Camzyos (mavacamten) accepted by the US regulator.

The firm wants to market the therapy to reduce the need for septal reduction therapy, adding to its earlier nod for the treatment of certain people with obstructive hypertrophic cardiomyopathy (HCM).

The US Food and Drug Administration is expected to make a decision by June 16, 2023, using data from the Phase III VALOR-HCM trial.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK